A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea® in Subjects With Neovascular Age-related Macular Degeneration

This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, Pharmacokinetics (PK), and immunogenicity of SB15 compared to Eylea® in subjects with neovascular AMD.

Study Overview

• Status: Completed
• Conditions: Neovascular Age-related Macular Degeneration
• Intervention / Treatment: Drug: SB15 (Proposed aflibercept biosimilar); Drug: Eylea (Aflibercept)

Detailed Description

Subjects will be randomised in a 1:1 ratio to receive either SB15 or Eylea® (administered via intravitreal [IVT] injection 2 mg [0.05 mL] every 4 weeks for the first 3 months (i.e., at Weeks 0, 4, and 8), followed by 2 mg [0.05 mL] once every 8 weeks). At Week 32, subjects in Eylea® treatment group will be randomised again in a 1:1 ratio to either continue on Eylea® treatment or be transitioned to SB15 treatment. In the 8-week treatment cycle, IPs (SB15 or Eylea®) will be administered up to Week 48, and the last assessment will be done at Week 56, corresponding to the end of follow-up for all subjects.

• Study Type: Interventional
• Enrollment (Actual): 449
• Phase: Phase 3

Contacts and Locations

Study Locations

• Croatia
  • Osijek, Croatia
    • SB Investigative Site
  • Rijeka, Croatia
    • SB Investigative Site
• Czechia
  • Brno, Czechia
    • SB Investigative Site
  • Hradec Králové, Czechia
    • SB Investigative Site
  • Praha 10, Czechia
    • SB Investigative Site
  • Praha 5, Czechia
    • SB Investigative Site
• Estonia
  • Kohtla-Järve, Estonia
    • SB Investigative Site
  • Tallinn, Estonia
    • SB Investigative Site
• Hungary
  • Budapest, Hungary
    • SB Investigative Site
  • Debrecen, Hungary
    • SB Investigative Site
  • Pécs, Hungary
    • SB Investigative Site
  • Szeged, Hungary
    • SB Investigative Site
  • Zalaegerszeg, Hungary
    • SB Investigative Site
• Japan
  • Aichi, Japan
    • SB Investigative Site
  • Fukuoka, Japan
    • SB Investigative Site
  • Inashiki-gun, Japan
    • SB Investigative Site
  • Kagoshima, Japan
    • SB Investigative Site
  • Nagasaki-Shi, Japan
    • SB Investigative Site
  • Osaka, Japan
    • SB Investigative Site
  • Saitama, Japan
    • SB Investigative Site
  • Tokyo, Japan
    • SB Investigative Site
• Korea, Republic of
  • Ansan, Korea, Republic of
    • SB Investigative Site
  • Busan, Korea, Republic of
    • SB Investigative Site
  • Daegu, Korea, Republic of
    • SB Investigative Site
  • Seongnam, Korea, Republic of
    • SB Investigative Site
  • Seoul, Korea, Republic of
    • SB Investigative Site
• Latvia
  • Riga, Latvia
    • SB Investigative Site
• Poland
  • Bydgoszcz, Poland
    • SB Investigative Site
  • Katowice, Poland
    • SB Investigative Site
  • Kraków, Poland
    • SB Investigative Site
  • Tarnów, Poland
    • SB Investigative Site
  • Łódź, Poland
    • SB Investigative Site
• Russian Federation
  • Kovrov, Russian Federation
    • SB Investigative Site
  • Moscow, Russian Federation
    • SB Investigative Site
  • Novosibirsk, Russian Federation
    • SB Investigative Site
  • Saint Petersburg, Russian Federation
    • SB Investigative Site
• United States
  • Colorado
    • Colorado Springs, Colorado, United States, 80909
      • SB Investigative Site
  • Maryland
    • Chevy Chase, Maryland, United States, 20815
      • SB Investigative Site
  • Texas
    • Abilene, Texas, United States, 79606
      • SB Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 48 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 50 years at Screening
2. Treatment naïve, *active subfoveal choroidal neovascularisation (CNV) lesion secondary to AMD in the study eye
3. The area of CNV must occupy at least 50% of total lesion in the study eye
4. Total lesion area ≤ 9.0 Disc Areas (DA) in size (including blood, scars, and neovascularisation) in the study eye
5. BCVA of 20/40 to 20/200 (letter score of 73 to 34, inclusive) using ETDRS charts or 2702 series Number charts in the study eye at Screening and at Week 0 (Day 1) prior to randomisation
6. Non-childbearing potential female, OR childbearing potential female subjects or male subjects with their (respectively male or female) partners who agree to use at least two forms of appropriate contraception method that can achieve a failure rate of less than 1% per year from Screening until 3 months after the last IVT injection of IP
7. Written informed consent form (ICF) must be obtained from the subject prior to any study related procedure
8. Willingness and ability to undertake all scheduled visits and assessments

Exclusion Criteria:

1. Study eye: Sub- or intra-retinal haemorrhage that comprises more than 50% of the entire lesion or presence of blood with the size of 1 DA or more involving the centre of fovea
2. Study eye: Scar, fibrosis, or atrophy involving the centre of the fovea
3. Study eye: Presence of CNV due to other causes, such as ocular histoplasmosis, trauma, multifocal choroiditis, angioid streaks, history of choroidal rupture, or pathologic myopia
4. Study eye: Presence of retinal pigment epithelial tears or rips involving the macula
5. Study eye: Presence of macular hole at any stage
6. Study eye: Any concurrent macular abnormality other than AMD which could affect central vision or the efficacy of IP
7. Study eye: Any concurrent ocular condition which, in the opinion of the Investigator, could either confound the interpretation of efficacy and safety of IP or require medical or surgical intervention during the study period
8. Either eye: History or clinical evidence of diabetic retinopathy (except for mild non-proliferative diabetic retinopathy) or diabetic macular oedema (DME)
9. Study eye: Current vitreous haemorrhage
10. Either eye: Any previous IVT anti-vascular endothelial growth factor (VEGF) treatment
11. Any previous systemic anti-VEGF treatment
12. Study eye: History of treatment involving macula such as macular laser photocoagulation, photodynamic therapy (PDT), transpupillary thermotherapy (TTT), radiation therapy, or any ocular treatment for neovascular AMD
13. Any systemic treatment or therapy (including prescribed herbal medication) to treat neovascular AMD within 30 days prior to randomisation. However, dietary supplements, vitamins, or minerals will be allowed.
14. Study eye: History of vitrectomy, scleral buckling (encircling), glaucoma filtration surgery, corneal transplantation, or pan-retinal photocoagulation
15. Study eye: Previous ocular (intraocular and peribulbar) corticosteroids injection/implant within 1 year prior to randomisation
16. Study eye: Topical ocular corticosteroids administered for ≥ 30 consecutive days or for ≥ 60 nonconsecutive days within 90 days prior to randomisation
17. Use of systemic corticosteroids for 30 or more consecutive days within 90 days prior to randomization (inhaled steroid is permitted).
18. Study eye: Any other intraocular surgery or periocular surgery within 90 days prior to randomisation, except for lid surgery, which may not have taken place within 30 days prior to randomisation.
19. Current use of medications known to be toxic to the lens, retina, or optic nerve at Screening.
20. Study eye: Previous radiation therapy near the region of the study eye
21. Previous participation in clinical studies with IP to treat neovascular AMD in either eye.
22. Previous participation in clinical studies with IP to treat disease other than neovascular AMD within 90 days prior to randomisation (excluding dietary supplementary, vitamins, and minerals).
23. Subject with only one functional eye (defined as BCVA of counting finger or less on the eye with worse vision)
24. Study eye: Spherical equivalent of the refractive error demonstrating more than 6 diopters of myopia. For subjects who have undergone previous refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye cannot exceed 6 diopters of myopia.
25. Study eye: Aphakia or absence of the posterior capsule (unless it occurred as a result of a YAG laser posterior capsulotomy in association with prior posterior chamber IOL implantation)
26. Either eye: Active or suspected ocular and periocular infection at Screening or at randomisation
27. Either eye: Active intraocular inflammation including scleritis at Screening or at randomisation
28. Either eye: History of idiopathic or autoimmune-associated uveitis
29. Study eye: Uncontrolled ocular hypertension (defined as intraocular pressure [IOP] ≥ 25 mmHg despite treatment with anti-glaucoma medication) at Screening
30. Known allergic reactions and/or hypersensitivity to any component of Eylea or SB15
31. History of allergy to the fluorescein sodium for injection in angiography
32. History of a medical condition that would preclude scheduled study visits or safe use of IP in the opinion of the Investigator
33. Uncontrolled systemic disease including but not limited to uncontrolled diabetes mellitus (in the opinion of the Investigator), uncontrolled systemic hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg on optimal medical regimen), or uncontrolled atrial fibrillation (resting heart rate ≥ 110 beats per minutes) at Screening
34. Stroke, transient ischaemic attacks, or myocardial infarction within 180 days prior to randomisation
35. History of recurrent significant infections and/or current treatment for systemic infection
36. Severe renal impairment with dialysis or a history of renal transplant
37. Malignancy (other than non-melanoma skin cancer) under treatment or with history of metastatic disease
38. Women of childbearing potential who are pregnant, planning to become pregnant, lactating, or not using adequate birth control, as specified in protocol. For women of childbearing potential, a serum pregnancy test must result negative at Screening.
39. Employees of investigational sites, individuals directly involved with the conduct of the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SB15 (Proposed aflibercept biosimilar); Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.	Drug: SB15 (Proposed aflibercept biosimilar); Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.
Active Comparator: Eylea (Aflibercept); Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. At Week 32, subjects in Eylea group will re-randomized into SB15 or Eylea group. After re-randomization, subjects transited to SB15 group will receive SB15 2 mg (0.05 mL) once every 8 weeks until Week 48 and subjects remaining in Eylea group will continue to receive Eylea 2 mg (0.05 mL) once every 8 weeks until Week 48.	Drug: SB15 (Proposed aflibercept biosimilar); Subjects randomized into SB15 group will receive SB15 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48. Starting at Week 32, subjects transited from Eylea to SB15 will receive SB15 2 mg (0.05 mL) via intravitreal injection every 8 weeks.; Drug: Eylea (Aflibercept); Subjects randomized into Eylea group will receive Eylea 2 mg (0.05 mL) via intravitreal injection every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) once every 8 weeks until Week 48.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Best Corrected Visual Acuity (BCVA)	The VA was assessed using original series ETDRS charts or 2702 series number charts.	Baseline and Week 8

Collaborators and Investigators

• Sponsor: Samsung Bioepis Co., Ltd.
• Investigators: Principal Investigator: Se Joon Woo, Seoul National University Bundang Hospital, South Korea

Study record dates

Study Major Dates

• Study Start (Actual): June 23, 2020
• Primary Completion (Actual): April 15, 2021
• Study Completion (Actual): March 16, 2022

Study Registration Dates

• First Submitted: June 24, 2020
• First Submitted That Met QC Criteria: June 24, 2020
• First Posted (Actual): June 29, 2020

Study Record Updates

• Last Update Posted (Actual): February 5, 2024
• Last Update Submitted That Met QC Criteria: February 2, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Macular Degeneration; Wet Macular Degeneration; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Aflibercept
• Other Study ID Numbers: SB15-3001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No